Kidney Disease: Improving Global Outcomes
Chronic Kidney Disease 2024
This guideline holds 94 pages.
Summary
Comprehensive update to KDIGO CKD guidelines. SGLT2 inhibitors now Class I for CKD with or without diabetes to slow progression. Finerenone recommended in diabetic CKD. Updated GFR equations (2021 CKD-EPI without race coefficient) and revised staging criteria for cardiorenal syndrome.
How the evidence was graded
Grading system
Class I–II
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- Kidney Disease: Improving Global Outcomes
- Published
- 2024
- Region
- INT
- Language
- English
- Grading system
- Class I–II
Keywords
- CKD
- SGLT2i
- Finerenone
- eGFR
- Cardiorenal syndrome
- Diabetic nephropathy